INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Open-market purchaseVerified data

Frankel Stanley bought DTIL

Director · PRECISION BIOSCIENCES INC · Common Stock

Side
BUY
Value
$6,000
Shares
1,000
Price
$6
Executed
Sep 28, 2026
Disclosed
Sep 30, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Sep 28 executedSep 30, 2026 disclosed

DTIL · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
29/ 100 · ROUTINE
Methodology →
  • Transaction type+20 / 20

    Open-market purchase

  • Relative size+1 / 25

    $6K reported value · 2.5% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

    • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · DTIL

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    3
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    37.1K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    69.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    27
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$145K
    34.8K sh
    		Jan 22, 2026Jan 22, 2026
    traded Jan 22, 2026
    		+0dSEC FORM 4

    Evidence

    0
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    69.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    3
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    1,978 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,425 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    24
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Open-market sale · 10b5-1 plan
    		SELL$36K
    8,854 sh
    		Jan 21, 2026Jan 22, 2026
    traded Jan 21, 2026
    		+1dSEC FORM 4

    Evidence

    0
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    1,978 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,425 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    26.6K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    3,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    11
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    13.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    KA
    Kelly John AlexanderChief Financial Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    26.6K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    2,500 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    10.4K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SJ
    Smith J. JeffersonChief Research Officer
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    16.2K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    AM
    Amoroso MichaelDirector, President and CEO
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    8,888 sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    7
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    14.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    0
    SD
    Scimeca DarioGeneral Counsel and Secretary
    DTILPRECISION BIOSCIENCES INC
    Option exercise · 10b5-1 plan
    		M—
    14.9K sh
    		Jan 20, 2026Jan 22, 2026
    traded Jan 20, 2026
    		+2dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001628280-26-063980
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Sep 28, 2026
    Published
    Sep 30, 2026
    Ingested by INSIDER
    Nov 5, 02:14 UTC
    Last re-read
    Nov 5, 02:14 UTC

    Extracted facts

    Filer
    Frankel Stanley
    Role
    Director
    Transaction
    Open-market purchaseAs filed: “P”
    Asset
    PRECISION BIOSCIENCES INC
    Ticker
    DTIL
    Shares
    1,000
    Price per share
    $6
    Value
    $6,000
    Execution date (reported)
    Sep 28, 2026
    Owned after transaction
    41.5K shares
    Days from execution to publication
    2

    Calculation

    Value = shares × reported price per share

    • Shares: 1,000
    • Price: $6

    = $6,000

    What this establishes

    Frankel Stanley filed this Form 4 reporting a open-market purchase of DTIL on Sep 28, 2026. It became public on Sep 30, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Director
    Frankel Stanleycik:0001855726
    Issuer
    PRECISION BIOSCIENCES INCcik:0001357874

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.